Jove
Visualize
Contact Us

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

9.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
9.8K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

2.1K
2.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.7K
Ligand Binding Sites02:40

Ligand Binding Sites

15.4K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.4K
Enzyme Inhibition01:30

Enzyme Inhibition

93.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
93.2K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enantioselective OTUD7B fragment discovery through chemoproteomics screening and high-throughput optimisation.

Communications chemistry·2025
Same author

NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics.

Nature communications·2025
Same author

Expedited SARS-CoV-2 Main Protease Inhibitor Discovery through Modular 'Direct-to-Biology' Screening.

Angewandte Chemie (International ed. in English)·2024
Same author

One-Pot Oxidative Amidation of Aldehydes via the Generation of Nitrile Imine Intermediates.

The Journal of organic chemistry·2024
Same author

Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells.

Cancer discovery·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 23, 2026

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays
08:48

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays

Published on: November 29, 2014

14.5K

Lysine-Targeting Covalent Inhibitors.

Jonathan Pettinger1, Keith Jones1, Matthew D Cheeseman1

  • 1Cancer Research, UK, Cancer Therapeutics Unit, The Institute of Cancer Research, London, SW7 3RP, UK.

Angewandte Chemie (International Ed. in English)
|August 31, 2017
PubMed
Summary

Targeted covalent inhibitors offer a promising strategy to overcome cancer resistance by irreversibly inhibiting proteins. This review highlights lysine targeting as a viable, albeit challenging, approach for designing novel oncology drugs.

Keywords:
drug designinhibitorslysinemedicinal chemistrystructural biology

More Related Videos

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

12.6K
Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli
07:26

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli

Published on: December 26, 2020

4.4K

Related Experiment Videos

Last Updated: Feb 23, 2026

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays
08:48

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays

Published on: November 29, 2014

14.5K
An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

12.6K
Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli
07:26

Site Specific Lysine Acetylation of Histones for Nucleosome Reconstitution using Genetic Code Expansion in Escherichia coli

Published on: December 26, 2020

4.4K

Area of Science:

  • Drug Discovery
  • Medicinal Chemistry
  • Oncology

Background:

  • Acquired resistance in oncology necessitates novel therapeutic strategies.
  • Targeted covalent inhibitors (TCIs) are effective in circumventing drug resistance.
  • Small-molecule/protein crystal structures guide the design of TCIs with electrophilic warheads.

Purpose of the Study:

  • To review the principles of designing TCIs that target lysine residues.
  • To provide historical examples of lysine-targeting inhibitors.
  • To present recent advancements in lysine-targeted drug discovery for oncology.

Main Methods:

  • Literature review of TCI design principles.
  • Analysis of small-molecule/protein crystal structures.
  • Examination of historical and recent case studies in lysine targeting.

Main Results:

  • Lysine targeting presents unique challenges due to the basicity of its ϵ-amino group.
  • Despite challenges, lysine targeting offers a viable route for irreversible inhibition.
  • Recent developments show significant potential for lysine-targeted inhibitors in drug discovery.

Conclusions:

  • Lysine-targeting covalent inhibition is a developing strategy in oncology drug discovery.
  • Overcoming design challenges can unlock new therapeutic avenues.
  • Further research into lysine-targeted TCIs holds promise for future cancer treatments.